Amicus Therapeutics Expands Biologics Pipeline with New Preclinical Program for Cyclin-Dependent Kinase-Like 5 Deficiency With Acquisition Of MiaMed For $1.8M Cash And $4.7M In Amicus Stock
Paul Quintaro